

Karl-Benz-Straße 3 86825 Bad Wörishofen GERMANY

Tel.: +49 8247 3907-0 Fax: +49 8247 3907-77

Mail: info@dronania.de Web: www.dronania.de

DRONANIA pharmaceuticals GmbH • Karl-Benz-Straße 3 • 86825 Bad Wörishofen

Mycotrition GmbH

Gewerbestr. 8

D-82064 Straßlach

CERTIFICATE OF ANALYSIS NO. 1750048

Customer:

Sample Data

Sample name: Chaga powder, fruit body, organic

Mycotrition GmbH

Supplier batch: IOP-SRORGBHR17001

 Quantity delivered:
 875 kg

 Best before:
 2021-02-21

 DR-Batch:
 R1700064

 DR-No.:
 0010 2329

 Sample received:
 2017-03-20

Sample-ID: 41505 Testing started: 2017-03-20

Test Procedure

Procedure: PV_R_0026
Source: Dronania

RESULTS:

See following page(s)



RESULTS:

TESTS	METHOD	RELEASE SPECIFICATIONS	RESULTS
General propertie	s:		
Appearance	Visual	Powder-like, brownish solid	Complies
Odor	Organoleptic	Characteristic	Complies
Taste	Organoleptic	Characteristic	Complies
Identity:			77
Differentiation Powder / Extract / Spores	Microscopy	<u>Powder:</u> Mostly mycelia with tube-shaped structure and cell fragments; mixture of both is possible	Complies (see Annex)
Differentiation Mycel and fruit body	Microscopy	Fruit body: Cellular structures; mostly fragments	Complies (see Annex)
SEC-fingerprint	SEC acc. to PV_R_0080	SEC-fingerprint must comply with a powder-fingerprint	Complies (see Annex)
TLC-fingerprint	TLC	Characteristic bands must be detectable	Complies (see Annex)
Technological par	ameters:		
Bulk density	Ph. Eur. 2.9.34	Batch-specific	0.21 g/ml
Tapped density	Ph. Eur. 2.9.34	Batch-specific	0.32 g/ml
Angel of response	Ph. Eur. 2.9.36	Batch-specific	45°
Loss on drying	Dryer	1.0 – 15.0 %	6.1 %

Bad Woerishofen, 2017-03-28

DRONANIA pharmaceuticals GmbH

Karl-Benz-Strasse 3 D 86825 Bad Wörishofen

2: 08247 / 39 07 - 0 Fax: 08247 / 39 07-77

T.S.A.lly Dr. Tanja Schaller

Head of Quality Control

This report refers exclusively to the specified test object. Without written permission of the DRONANIA pharmaceuticals GmbH, this report may not be published in part.

The general contract and business conditions of the DRONANIA pharmaceuticals GmbH are valid at present version.



ANNEX:




Figure 1: Microscopic examination






Figure 2: SEC-fingerprint of sample solution




Figure 3: Thin-layer chromatogram (left: reference solution, right: sample solution)